107 SPRING STREET, SEATTLE, WA
Market cap: $41.5M (2/09/2026)
Price: $4.82
Atossa Therapeutics Approves 15:1 Reverse Stock Split Effective February 2, 2026
Atossa Therapeutics Estimates $40 Million Cash as of December 31, 2025
Receives FDA “Study May Proceed” Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
Reg. FD
Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration Statement for Additional Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Delisting Amendment
Correspondence
Submission Upload